| odanacatib (MK-0822) / Merck (MSD) |
NCT00769418: Study of Multiple Oral Doses of Odanacatib (MK0822) in Healthy Adults (0822-002) |
|
|
| Completed | 1 | 62 | Europe | odanacatib, MK0822, Comparator: Placebo | Merck Sharp & Dohme LLC | Osteoporosis | 12/04 | 09/06 | | |
NCT00863525: A Study to Assess the Effects of a Light Breakfast on the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) |
|
|
| Completed | 1 | 8 | US | odanacatib, MK0822, Comparator: Placebo | Merck Sharp & Dohme LLC | Osteoporosis | 12/04 | 06/06 | | |
NCT00863590: A Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Odanacatib (MK0822) in Healthy Volunteers |
|
|
| Completed | 1 | 24 | Europe | odanacatib, Comparator: odanacatib (Panel B), Comparator: odanacatib (Panel C), Comparator: odanacatib (Panel D) | Merck Sharp & Dohme LLC | Osteoporosis | 02/05 | 08/08 | | |
NCT00770159: A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED) |
|
|
| Completed | 1 | 78 | US | odanacatib, Comparator: placebo to MK0822 | Merck Sharp & Dohme LLC | Osteoporosis | 06/05 | 11/05 | | |
NCT01068262: Safety and Tolerability of Odanacatib (0822-059) |
|
|
| Completed | 1 | 44 | NA | Odanacatib, MK0822, Comparator: Placebo | Merck Sharp & Dohme LLC | Osteoporosis | 04/10 | 05/10 | | |
| Terminated | 1 | 19 | NA | Odanacatib, MK-0822, Placebo | Merck Sharp & Dohme LLC | Osteoporosis | 07/16 | 07/16 | | |
